A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/485 (2006.01)
Patent
CA 2546691
Oxycodone formulations are provided which produce substantially flat in vivo steady state plasma profiles. Tolerance levels associated with such profiles and tolerance levels associated with biphasic profiles are shown not to be statistically different. The substantially flat in vivo steady state plasma profiles are produced by dosage forms having substantially zero order in vitro release profiles. Such release profiles produce low single dose in vivo Cmax levels which can reduce the probability of adverse side effects.
L'invention porte sur des préparations d'oxycodone produisantin vivo des profils plasmatiques sensiblement constants. Les niveaux de tolérance associés à ces profils et ceux associés aux profils biphasés se sont avérés statistiquement identiques. Ces profils plasmatiques sensiblement constants in vivo sont produits par des formes posologiques présentant des profils <i> in vitro</i> d'ordre sensiblement nul. De tels profils de libération produisent <i>in vivo</i> pour une faible dose unique des niveaux de C¿max? pouvant réduire la probabilité d'effets secondaires adverses.
Hwang Stephen
Modi Nishit B.
Shivanand Padmaja
Alza Corporation
Ogilvy Renault Llp/s.e.n.c.r.l.,s.r.l.
LandOfFree
Once-a-day, oral, controlled-release, oxycodone dosage forms does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Once-a-day, oral, controlled-release, oxycodone dosage forms, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Once-a-day, oral, controlled-release, oxycodone dosage forms will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1946772